GOP Senators File Bill to Track Medicaid Costs of Cannabis Hospitalization

Two Republican senators introduced legislation Thursday that would mandate federal tracking of Medicaid costs tied to cannabis-related hospitalizations, marking the latest congressional effort to document marijuana's healthcare impact as legalization expands nationwide.

Sens. Ted Budd of North Carolina and Pete Ricketts of Nebraska filed the Marijuana Impact on Medicaid Act of 2026, which directs the Department of Health and Human Services secretary to collect and analyze hospitalization data linked to marijuana use. The bill comes as 24 states have legalized adult-use cannabis and 38 permit medical marijuana programs.

The legislation doesn't specify what qualifies as a "marijuana-related" hospitalization or how HHS would distinguish between direct cannabis toxicity, cannabinoid hyperemesis syndrome, or complications from unregulated products. That ambiguity has drawn immediate criticism from industry advocates who argue the bill could conflate black market product failures with legal cannabis safety records.

The Political Context

Budd and Ricketts represent states with sharply different cannabis policies. North Carolina maintains prohibition for recreational use while allowing a limited medical program approved in 2023. Nebraska voters rejected legalization measures in 2022 and 2024, making Ricketts one of the Senate's most vocal cannabis opponents.

The timing aligns with broader Republican efforts to highlight perceived costs of state-level legalization. Similar bills in previous sessions have stalled in committee, but the current Congress has shown renewed interest in cannabis oversight following reports of increased emergency room visits in some legal markets.

Yet proponents of federal cannabis reform point out that prohibition itself drives healthcare costs. Without access to legal, tested products, consumers turn to unregulated markets where contaminated or synthetic cannabinoids pose genuine health risks. Emergency departments in illegal states often see more severe complications than those in regulated markets.

Industry Response

Cannabis trade groups immediately pushed back on the bill's framing. The National Cannabis Industry Association has long argued that comprehensive federal data collection should include comparative analysis—tracking healthcare outcomes in legal versus illegal markets, measuring tax revenue gains, and accounting for reduced opioid prescriptions in medical marijuana states.

"If Congress wants real data, they should fund comprehensive research that includes the public health benefits documented in state after state," said one industry lobbyist speaking on background. "Cherry-picking hospitalization costs without context is designed to produce a predetermined conclusion."

The pharmaceutical industry's role in opioid-related hospitalizations—which cost Medicaid billions annually—rarely faces similar legislative scrutiny, reform advocates note. Cannabis hospitalization rates, even in legal markets, remain a fraction of alcohol or prescription drug emergency visits.

What Happens Next

The bill faces an uncertain path in a closely divided Senate. It would need bipartisan support to advance from committee, and Democrats have shown little appetite for legislation that frames cannabis solely through a cost-burden lens without acknowledging criminal justice reform benefits or medical applications.

HHS already collects some marijuana-related healthcare data through existing programs, though advocates for the bill argue current tracking lacks specificity around Medicaid spending. The Congressional Budget Office would need to score the legislation's implementation costs before any floor vote.

Meanwhile, comprehensive cannabis reform bills—including the SAFER Banking Act and various descheduling proposals—remain stalled despite broader public support for legalization. This Medicaid-focused measure may gain traction among fiscal conservatives even if broader reform continues to face resistance.

The legislation arrives as the cannabis industry navigates a challenging federal landscape. The Drug Enforcement Administration's pending decision on rescheduling marijuana from Schedule I to Schedule III could reshape the entire regulatory framework, potentially rendering state-by-state cost tracking less relevant if federal medical authorization follows.

This article is based on original reporting by www.marijuanamoment.net.